Literature DB >> 23924655

Declaration of transparency for each research article.

Douglas G Altman, David Moher.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23924655      PMCID: PMC3737035          DOI: 10.1136/bmj.f4796

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
“It is the responsibility of everyone involved to ensure that the published record is an unbiased, accurate representation of research.”1 The research record is often manipulated for short term gain but at the risk of harm to patients. The medical research community needs to implement changes to ensure that readers obtain the truth about all research, especially reports of randomised trials, which hold a special place in answering what works best for patients. Failure to publish the findings of all studies, especially randomised trials, seriously distorts the evidence base for clinical decision making. A recent systematic review of reboxetine for treating depression found that almost three quarters of included patients were in unpublished trials.2 Of 904 completed trials of interventions for acute ischaemic stroke (1955-2008), a fifth were not properly published, “several of which may be large enough to influence clinical practice and the findings of systematic reviews and meta-analyses.”3 Bad as non-publication is, incomplete or misleading publications cause greater problems. Results of clinical trials published in peer reviewed publications may differ from what was previously submitted to regulatory agencies,4 5 6 with the published data being more positive. The primary outcome often differs from what the researchers had stated in the trial protocol7 8 or clinical trial registry.9 10 Selective non-publication favours statistically significant findings, biasing the literature.11 12 Furthermore, authors often distort the presentation and interpretation of their findings. One study found that such “spin” was common in 72 reports of randomised controlled trials with statistically non-significant primary outcomes.13 Similar findings have been reported recently for studies of the accuracy of diagnostic tests.14 Peer review is failing to ensure that journal articles contain the key clinical and methodological details that readers need. Reviews of published reports of randomised trials have found common deficiencies in the details of the interventions being evaluated,15 16 participant eligibility criteria,17 and outcomes.18 19 Details of study methods are also often inadequate, especially in relation to allocation. A 2006 study found that only a third of trial reports described how the randomisation sequence was generated and only a quarter described an adequate method of allocation concealment.20 A review of 357 phase III oncology trials concluded that “numerous items remained unreported for many trials.”21 Harms too are poorly reported.22 23 The problems associated with publishing and reporting other types of research may be worse than for randomised trials. Although less intensively studied, similar concerns have been expressed in relation to epidemiology,24 25 pharmacoepidemiology,26 diagnosis research,27 prognosis research,28 and preclinical research.29 30 Of course, good reporting is not the same as high quality research. But a full and clear report allows readers to judge a study’s reliability and relevance. There are concerns that commercially sponsored research may be more likely to remain unpublished,2 31 but when published these trials are reported more fully.32 So what is needed? Published research articles should provide a clear and transparent description of how researchers conducted their study and what they found. Omission of important details of methods or study conduct should be deemed unacceptable, and journals should not publish them. Although detection of some deficiencies requires external information (for example, from a trials register or protocol), most deficiencies are inherent in a submitted manuscript and should be detected. Despite the availability of reporting guidelines such as CONSORT,33 improvements are slow to materialise.34 By not making results of their research easily accessible, researchers are withholding knowledge, in contravention of the Declaration of Helsinki. Not only are current practices questionable on moral and scientific grounds, failure to publish all research findings is a massive waste of scarce resources and diminishes the social value of the research.35 Researchers and funding organisations also fail the public when research findings are published in a misleading or inadequate way. Scientifically, this harms systematic reviewers who want to aggregate all of the evidence. Reviewing a partial picture provides biased and less precise estimates of effectiveness and safety than when the full information is used, and it may compromise the identification of what works best for patients. We have a proposal that can be acted on almost immediately. We suggest that authors should sign a publication transparency declaration (box) as part of every journal submission. The same declaration could be appropriate for submissions in other contexts—for example, to regulatory agencies.

Transparency declaration

The lead author* affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. *The manuscript’s guarantor. Editors and editorial groups can support this initiative by updating their instructions to authors so that a completed publication transparency pledge is required as part of the submission process. We see this action as a necessary scientific analogue of the current widespread practice of asking authors about conflicts of interest. Subsequent revelation of withheld or incorrect information would be evidence of scientific misconduct for which various actions could be taken. We hope that this step will encourage authors to reflect more carefully on how they write their article and encourage them to check that they have adhered to relevant reporting guidelines. The BMJ, for which one of us (DGA) is the senior statistics editor, and BMJ Open are leading the way by implementing this policy immediately. We invite other journals to do likewise and support the transparency declaration on the EQUATOR website (www.equator-network.org). The scientific community and the public at large deserve an accurate and complete record of research; we need to make changes to ensure that we will get one. Widespread endorsement and implementation of a publication transparency declaration is one way to help to get the maximum value from medical research. It will, however, have no influence on the non-publication of studies, which is a continuing disgrace.
  35 in total

1.  When one depends on the other: reporting of interaction in case-control and cohort studies.

Authors:  Mirjam J Knol; Matthias Egger; Pippa Scott; Mirjam I Geerlings; Jan P Vandenbroucke
Journal:  Epidemiology       Date:  2009-03       Impact factor: 4.822

2.  What is missing from descriptions of treatment in trials and reviews?

Authors:  Paul Glasziou; Emma Meats; Carl Heneghan; Sasha Shepperd
Journal:  BMJ       Date:  2008-06-28

3.  Comparison of randomized controlled trial registry entries and content of reports in surgery journals.

Authors:  Rachel Rosenthal; Kerry Dwan
Journal:  Ann Surg       Date:  2013-06       Impact factor: 12.969

4.  The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed.

Authors:  Sally Hopewell; Susan Dutton; Ly-Mee Yu; An-Wen Chan; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

5.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  BMJ       Date:  2010-03-23

Review 6.  Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

Authors:  Dirk Eyding; Monika Lelgemann; Ulrich Grouven; Martin Härter; Mandy Kromp; Thomas Kaiser; Michaela F Kerekes; Martin Gerken; Beate Wieseler
Journal:  BMJ       Date:  2010-10-12

7.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

8.  Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.

Authors:  Erick H Turner; Daniel Knoepflmacher; Lee Shapley
Journal:  PLoS Med       Date:  2012-03-20       Impact factor: 11.069

Review 9.  Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals.

Authors:  Lucy Turner; Larissa Shamseer; Douglas G Altman; Laura Weeks; Jodi Peters; Thilo Kober; Sofia Dias; Kenneth F Schulz; Amy C Plint; David Moher
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

Review 10.  Prospective registration and outcome-reporting bias in randomized controlled trials of eczema treatments: a systematic review.

Authors:  Helen Nankervis; Akerke Baibergenova; Hywel C Williams; Kim S Thomas
Journal:  J Invest Dermatol       Date:  2012-07-26       Impact factor: 8.551

View more
  17 in total

1.  Inconsistencies and inaccuracies in reporting on choice of endpoints and of statistical results in RCT of maternal diet.

Authors:  D W Lewis; D A Fields; D B Allison
Journal:  Pediatr Obes       Date:  2015-04-20       Impact factor: 4.000

Review 2.  Drug development: how academia, industry and authorities interact.

Authors:  Silvio Garattini; Norberto Perico
Journal:  Nat Rev Nephrol       Date:  2014-08-05       Impact factor: 28.314

3.  West Meets East.

Authors:  Giuseppe Remuzzi
Journal:  Kidney Dis (Basel)       Date:  2015-04-24

4.  Explanation and Elaboration Document for the STROBE-Vet Statement: Strengthening the Reporting of Observational Studies in Epidemiology-Veterinary Extension.

Authors:  A M O'Connor; J M Sargeant; I R Dohoo; H N Erb; M Cevallos; M Egger; A K Ersbøll; S W Martin; L R Nielsen; D L Pearl; D U Pfeiffer; J Sanchez; M E Torrence; H Vigre; C Waldner; M P Ward
Journal:  J Vet Intern Med       Date:  2016-11-07       Impact factor: 3.333

5.  Transparency in the International Journal of Medical Students.

Authors:  Francisco J Bonilla-Escobar; Aisha K Gharaibeh; Stuart J Mires; Hulegar A Abhishek
Journal:  Int J Med Stud       Date:  2014-02-28

6.  Methodological reporting of randomized trials in five leading Chinese nursing journals.

Authors:  Chunhu Shi; Jinhui Tian; Dan Ren; Hongli Wei; Lihuan Zhang; Quan Wang; Kehu Yang
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

7.  Meta-audit of laboratory ISO accreditation inspections: measuring the old emperor's clothes.

Authors:  Ian G Wilson; Michael Smye; Ian J C Wallace
Journal:  Microbiologyopen       Date:  2015-12-01       Impact factor: 3.139

8.  Why articles are retracted: a retrospective cross-sectional study of retraction notices at BioMed Central.

Authors:  Elizabeth C Moylan; Maria K Kowalczuk
Journal:  BMJ Open       Date:  2016-11-23       Impact factor: 2.692

Review 9.  Reporting transparency: making the ethical mandate explicit.

Authors:  Stuart G Nicholls; Sinéad M Langan; Eric I Benchimol; David Moher
Journal:  BMC Med       Date:  2016-03-16       Impact factor: 8.775

10.  Publishing descriptions of non-public clinical datasets: proposed guidance for researchers, repositories, editors and funding organisations.

Authors:  Iain Hrynaszkiewicz; Varsha Khodiyar; Andrew L Hufton; Susanna-Assunta Sansone
Journal:  Res Integr Peer Rev       Date:  2016-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.